Aurobindo Pharma Ltd has received a warning letter from capital markets regulator Sebi for non-disclosure of details related to an ongoing audit of one of its manufacturing units in Hyderabad and observations made by the USFDA.
from Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/OXraUBz
Home »
Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com
» Aurobindo Pharma receives Sebi's warning letter over ongoing USFDA audit
https://ift.tt/LBotTrZ
No comments:
Post a Comment